We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.14 | 2.10 | 2.18 | 2.20 | 2.19 | 2.19 | 604,698 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.93 | 7.33M |
Date | Subject | Author | Discuss |
---|---|---|---|
20/1/2018 07:31 | The columns on the site show the hard life Lupus sufferers lead. This one in particular shows the downsides of taking immunosuppresents. Something that hopefully Lupuzor can overcome. | hamhamham1 | |
20/1/2018 06:45 | A rewrite of the rns on a good Lupus website. Will be interesting to see if any comments get added over time. | hamhamham1 | |
19/1/2018 23:58 | Thanks for writing it concisely and clearly. | ashehzi | |
19/1/2018 22:22 | Oilbagger 10350 Post of the day ! | devereaux | |
19/1/2018 21:29 | One reason not to have a stop loss on AIM is that you are playing into the MMs hands by making it easier for them to manipulate the share price. It is surprising how easy MMs can drop a share price down 20% to 30% for no reason and then bring it straight back up. On the way down they can pick up cheap share to sell when they return to the original price. They also narrow and widen the spreads to make sells look like buys and buys look like sells. This plus the fact that they can delay reporting of some larger trades makes it is almost impossible to tell if these larger trades are a buys or sells. Hence, for a share like IMM it is best to ignore the short term fluctuations; if you believe results will be good hold tight and ignore the background noise from posters who have ulterior motives. | oilbagger | |
19/1/2018 21:23 | In case the below is interesting, I asked Breq over at Stocko... what she thought of events over the last 6 months. She said (my words): You only know 3 new things. The share price has trebled. The robust safety profile has continued to the end of the trial. Some patients and clinicians have requested access to Lupuzor. Her explanation was (I'm only including the stuff I understood and was not too intrusive) the trial is 200 patients at 30 sites with Mauritius having 30 patients. So that's about 6 patients for each site except Mauritius. If the Lupuzor allocation is randomly allocated then some of those 29 sites will have patients who mostly or all are allocated Lupuzor. If Lupuzor 'works' then these clinicians will seek to request Lupuzor for all their patients having observed good results for their group. If Lupuzor doesn't work - is no better than placebo - then at say a 30% placebo responder rate there is only a very small chance of a group of say 5 or 6 patients all of mostly responding and so encouraging the clinician to request Lupuzor for her group. If a clinician has only 1 or 2 patients out of 6 responding then they're more likely to say: 'This study publishes top line results in a couple of months so let's wait until then and if good request Lupuzor' I asked if the share price increase suggested a leak. She said no. It's double blinded. She scanned recent shares and trial results and mentioned Ohr Pharmaceutical which doubled in the month leading up to a trial failure. She said a collapsing share price was however suggestive of trial failure - gloomy Lupuzor clinicians at conferences. So I guess one could read from the share price that Lupuzor will be better than placebo. Just how much better we'll know by end March. Hope that makes sense. No advice to buy intended. Breq's analysis not mine. | paxman | |
19/1/2018 20:38 | ytsa2 there are many ways that MMs can manipulate the share price. Once example taken from hxxps://goo.gl/vWT7w "Say a market maker that provides a quote for a particular company has perceived that demand for said company’s stock has been increasing over the past week, and has increased the share price accordingly (so that existing holders will sell shares to him) to meet said demand. Through discussions with other market participants (fellow market makers, brokers, etc.) he understands that the recent increase in demand for shares is due to an anticipated news release from the company that the investment community overall believes will be positive. He therefore appreciates that it would be sensible to hold a greater number of shares going into this period than he would be accustomed to, so that were the news to indeed be positive, he would not be required to push the bid up so aggressively and create a spike in the process. Accordingly, during trading when a number of sells hit his order book, the market maker – having spotted that a large block of shares is available at a lower price through the hitting of a ‘stop loss’ (an instrument used by an investor to automatically sell shares once the share price hits a certain price, thereby limiting the investor’s loss) – duly drops the bid (on occasions significantly) more than would be considered necessary to balance the book. The stop loss order is executed, the investor is knocked out of his position, and the market maker now has a large supply of cheap shares that he can sell at a tidy profit to investors when the anticipated good news does arrive." | oilbagger | |
19/1/2018 19:47 | Yes people need to stop fussing lol | davr0s | |
19/1/2018 19:46 | Wasn't the big sell at 16.35(about 63000) the uncrossing trade? | kevioio | |
19/1/2018 19:39 | With AIM stocks is the share price driven automatically by volumes bought/sold in anyway. If not how do the MMs change the price. Be interested to know from anybody who knows a bit more. From posts on here they appear to be able to do what they want. If a big institution wants to purchase or sell a lot of shares can tney tell the MM within reason what they are prepared to pay or acheive and thus lower price accordingly | ytsa2 | |
19/1/2018 19:25 | Yep I just don't like people feeling bad. Sad maybe but there's enough bad stuff in the world and think no reason to be unhappy here. Remarkomsac I do appreciate the input just care that's all. | hamhamham1 | |
19/1/2018 19:21 | Ham: In fairness there are a lot worse thean remar. Admittedly I am enjoying the correlation of stock price increase and thumbs down on positive posts.:-) | l0ngterm | |
19/1/2018 19:06 | Pointless entertaining Rem, he is what is known as the “living dead”. | mustau | |
19/1/2018 19:02 | I'd like to think it his attempt at humour, hamhamham but then again ....he is like that on the idp board | lukead | |
19/1/2018 18:17 | Nice high close for the weekend. | abbotslynn | |
19/1/2018 18:00 | Remarkonsoc. Without wishing to come across wrong, I think you need to relax a bit. Everytime the share goes down a couple of pence you post messages ending something like "Oh god!". And your last is along the same lines. Please just relax or do not do share dealing for your own health. This message is meant with the best intentions. | hamhamham1 | |
19/1/2018 17:07 | The finish didn't really reflect the days trading. Forced down at the end to keep a lid on things. But come Monday am sure the bump start will resume. GLA. | hamhamham1 | |
19/1/2018 16:42 | For every seller, there's a buyer ;) | hamhamham1 | |
19/1/2018 16:39 | Big sell logged at 4.35 wot did it I suspect. Not a bad week overall though and everything points to more to come. | husbod | |
19/1/2018 16:31 | Very poor finish for amount of buys since 12 clock . Has to tick up on mon if buying continues | aussieb3 | |
19/1/2018 16:31 | really surprised this hasn't risen more, but GLA let's see what transpires next week....DYOR | qs99 | |
19/1/2018 16:30 | i hate to be wrong! | adejuk | |
19/1/2018 15:59 | someuwin, me too - I'm surprised it hasn't gone closing only tbh...they must be close to their 2% ceiling | sportbilly1976 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions